HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology

MLA

Bartley, Angela N., et al. “HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.” Archives of Pathology & Laboratory Medicine, vol. 140, no. 12, Dec. 2016, p. 1345. EBSCOhost, https://doi.org/10.5858/arpa.2016-0331-CP;

APA

Bartley, A. N., Washington, M. K., Ventura, C. B., Ismaila, N., Colasacco, C., Benson, A. B., III, Carrato, A., Gulley, M. L., Jain, D., Kakar, S., Mackay, H. J., Streutker, C., Tang, L., Troxell, M., & Ajani, J. A. (2016). HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Archives of Pathology & Laboratory Medicine, 140(12), 1345. https://doi.org/10.5858/arpa.2016-0331-CP;

Chicago

Bartley, Angela N., Mary Kay Washington, Christina B. Ventura, Nofisat Ismaila, Carol Colasacco, Al. B. Benson III, Alfredo Carrato, et al. 2016. “HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.” Archives of Pathology & Laboratory Medicine 140 (12): 1345. doi:10.5858/arpa.2016-0331-CP;